Navigation Links
ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Date:3/6/2009

et="_new">http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics
    Dr. Steve Pakola, CMO
    Tel: +1-(212)-201-0920
    steve.pakola@thrombogenics.com

    Dr. Patrik De Haes, CEO
    Tel: +32-16-75-13-10
    patrik.dehaes@thrombogenics.com

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren
    Tel: +44-(0)207-638-95-71
    amber.bielecka@citigatedr.co.uk



'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
2. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
3. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
4. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
5. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
6. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
7. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
8. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
11. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, announced today that the first patient ... clinical trial of AGT-181 in patients with attenuated ... AGT-181 is an investigational enzyme replacement therapy (ERT) ... severe form of MPS I, Hurler syndrome, is ...
(Date:9/2/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), today ... be presenting at the Rodman & Renshaw 17th Annual Global ... at 9:35 a.m. ET on Thursday, September 10, 2015. ... via live audio webcast which can be accessed by visiting ... http://www.aethlonmedical.com . The webcast will be archived for thirty ...
(Date:9/2/2015)... , Sept. 2, 2015  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... , President and Chief Executive Officer, will present ... Global Investment Conference, sponsored by H.C. Wainwright ... September 8-10, 2015 at the St. Regis Hotel ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
(Date:9/2/2015)... ... September 02, 2015 , ... On September 9, 2015, over 27,000 people from ... largest single-company convention to date for the state of Utah. , “We are thrilled ... event,” states David Stirling, doTERRA CEO. “One of the most exciting elements of our ...
(Date:9/2/2015)... ... ... “ G-Hold ” was featured on NewsWatch as part of its monthly Tech Report, ... technology expert and special reporter for NewsWatch, conducted the review and shared with viewers ... the likelihood of it dropping. , Tablets like the iPad and Samsung Galaxy Tab ...
(Date:9/2/2015)... ... 2015 , ... The payroll conference theme this year is ... covering legislative updates, including unemployment, global payroll best practices, and the latest trends ... Software, the American Payroll Association, Barnett Associates, and the IRS, will keep payroll ...
(Date:9/2/2015)... ... September 02, 2015 , ... Pentec Health, Inc., a national leader ... for an impressive sixth consecutive year. Less than 5 % of this year’s 5000 ... the “health” sector. Pentec’s 3-year revenue growth rate of 65% sustained its most ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... If the man who mowed down 32 persons at Virginia Tech ... you call the man who has devised a computer game ... rampage, players control an image of Korean-born gunman Cho Seung-hui. Screams ... the other characters. ,21-year-old Ryan Lambourn, an Australian, ...
... reward the federal government with their vote at the next ... the same time he concedes that two bad post-budget polls ... ,"I'm confident that come Election Day, people will reward ... Abbott was quoted. He said he was confident voters had ...
... extended time are the most common but contentious accommodation ... and/or AD/HD taking college entrance and licensing exams. According ... Practice, students given extra time respond to exams similarly ... ,According to my research, there is no real evidence ...
... Director-General of the World Health Organization, has called upon all member ... that would handicap the organization in the fight contain bird blu. ... . I would fail you," said he said in a speech ... countries, Chan said that "you are tying my hands, you're muffling ...
... past, the newborns umbilical cord was not clamped right ... naturally. This practice , known as late clamping, was ... immediately after the infant is expelled. However, this new ... studies on the importance of when clamping should be ...
... on animals, conducted by the National Toxicology Program (NTP), ... as hexavalent chromium (chromium 6) causes cancer when ... ,Hexavalent chromium compounds are often used in electroplating, leather ... some drinking water sources. ,The two-year study ...
Cached Medicine News:Health News:Australian Devises Online Game Based on Virginia Tech Shootout 2Health News:Tony Abbott Confident Of Australias Vote For Performance Not Promise 2Health News:WHO Director Urges Nations to Share Bird Flu Virus Strains 2Health News:Late Clamping of Umbilical Cord may Reduce Anemia in Children 2Health News:Late Clamping of Umbilical Cord may Reduce Anemia in Children 3
Coat-A-Count PAP IRMA,is an immunoradiometric assay designed,for the quantitative measurement of,prostatic acid phosphatase (PAP) in,serum. It is intended strictly for in vitro,diagnostic u...
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
Abbott offers an array of both in-vitro and molecular diagnostic tests for the detection and monitoring of cancerous conditions in patients....
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
Medicine Products: